The Journal of the American Dental Association
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Am Dent Assoc, Vol 134, No 2, 200-207.
© 2003 American Dental Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SCULLY, C.
Right arrow Articles by LOZADA-NUR, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SCULLY, C.
Right arrow Articles by LOZADA-NUR, F.
Related Collections
Right arrow Endodontics

DENTISTRY & MEDICINE

JADA Continuing Education

The diagnosis and management of recurrent aphthous stomatitis

A consensus approach



CRISPIAN SCULLY, C.B.E.. M.D., Ph.D., M.D.S., F.D.S.R.C.S., F.D.S.R.C.P.S., F.F.R.C.S.I., F.D.S.R.C.S.E., F.R.C.Path., F.Med.Sci., MEIR GORSKY, D.M.D. and FRANCINA LOZADA-NUR, D.D.S., M.S., M.P.H.
Background. Recurrent aphthous stomatitis, or RAS, is a common oral disorder of uncertain etiopathogenesis for which symptomatic therapy only is available. This article reviews the current data on the etiopathogenesis, diagnosis and management of RAS in a primary care setting.

Methods. The authors reviewed publications on Medline from 1995 through 2000, the period since the last major reviews were published.

Results. RAS may have an immunogenetic background owing to cross-reactivity with Streptococcus sanguis or heat shock protein. Predisposing factors seen in a minority include haematinic (iron, folate or vitamin B12) deficiency, stress, food allergies and HIV infection. While topical corticosteroids remain the mainstay for therapy, a number of other immunomodulatory modalities now are available.

Conclusions. There is still no conclusive evidence relevant to the etiopathogenesis of RAS, and therefore therapy can attempt only to suppress symptoms rather than to address the basic issues of susceptibility and prevention.

Clinical Implications. In the majority of patients, symptomatic relief of RAS can be achieved with topical corticosteroids alone, with other immunomodulatory topical agents or by combination therapy.




This article has been cited by other articles:


Home page
 Arch DermatolHome page
A. Bruce and R. S. Rogers III
New and Old Therapeutics for Oral Ulcerations
Arch Dermatol, April 1, 2007; 143(4): 519 - 523.
[Full Text] [PDF]

Home page
 NEJMHome page
C. Scully
Clinical practice. Aphthous ulceration.
N. Engl. J. Med., July 13, 2006; 355(2): 165 - 172.
[Full Text] [PDF]

Home page
 J. Dent. Res.Home page
M.A. Gonzalez-Moles and C. Scully
Vesiculo-erosive Oral Mucosal Disease--Management with Topical Corticosteroids: (1) Fundamental Principles and Specific Agents Available
J. Dent. Res., April 1, 2005; 84(4): 294 - 301.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
G. Mumcu, T. Ergun, N. Inanc, I. Fresko, T. Atalay, O. Hayran, and H. Direskeneli
Oral health is impaired in Behcet's disease and is associated with disease severity
Rheumatology, August 1, 2004; 43(8): 1028 - 1033.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright©1995-2003 American Dental Association (ADA).
Reproduction or republication strictly prohibited without prior written permission of ADA.